CA2315032A1 - Formulations pharmaceutiques d'adn comportant du citrate ou de la triethanolamine ou des combinaisons de ces composes - Google Patents

Formulations pharmaceutiques d'adn comportant du citrate ou de la triethanolamine ou des combinaisons de ces composes Download PDF

Info

Publication number
CA2315032A1
CA2315032A1 CA002315032A CA2315032A CA2315032A1 CA 2315032 A1 CA2315032 A1 CA 2315032A1 CA 002315032 A CA002315032 A CA 002315032A CA 2315032 A CA2315032 A CA 2315032A CA 2315032 A1 CA2315032 A1 CA 2315032A1
Authority
CA
Canada
Prior art keywords
nucleic acid
dna
citrate
triethanolamine
present
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002315032A
Other languages
English (en)
Inventor
Robert K. Evans
David B. Volkin
Mark W. Bruner
Zheng Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Merck and Co Inc
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB9801099.4A external-priority patent/GB9801099D0/en
Application filed by Individual filed Critical Individual
Publication of CA2315032A1 publication Critical patent/CA2315032A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biotechnology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention se rapporte à des formulations, à base d'acide nucléique, de produits pharmaceutiques comportant du citrate ou de la triéthanolamine à des concentrations permettant d'accroître la stabilité de l'acide nucléique. Ces formulations conviennent aux situations de stockage prolongé pouvant se produire lors de la période de distribution et/ou de stockage avant utilisation.
CA002315032A 1997-12-23 1998-12-22 Formulations pharmaceutiques d'adn comportant du citrate ou de la triethanolamine ou des combinaisons de ces composes Abandoned CA2315032A1 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US6872197P 1997-12-23 1997-12-23
US60/068,721 1997-12-23
GBGB9801099.4A GB9801099D0 (en) 1998-01-20 1998-01-20 DNA pharmaceutical formulations comprising citrate or triethanolamine
GB9801099.4 1998-01-20
PCT/US1998/027310 WO1999032503A1 (fr) 1997-12-23 1998-12-22 Formulations pharmaceutiques d'adn comportant du citrate ou de la triethanolamine ou des combinaisons de ces composes

Publications (1)

Publication Number Publication Date
CA2315032A1 true CA2315032A1 (fr) 1999-07-01

Family

ID=26312979

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002315032A Abandoned CA2315032A1 (fr) 1997-12-23 1998-12-22 Formulations pharmaceutiques d'adn comportant du citrate ou de la triethanolamine ou des combinaisons de ces composes

Country Status (5)

Country Link
EP (1) EP1042347A4 (fr)
JP (1) JP2001526292A (fr)
AU (1) AU1940599A (fr)
CA (1) CA2315032A1 (fr)
WO (1) WO1999032503A1 (fr)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5117732B2 (ja) * 2007-01-29 2013-01-16 株式会社 メドレックス 外用剤用の低刺激性溶解助剤
EP3823677A4 (fr) * 2018-07-19 2022-06-01 Helixmith Co., Ltd. Compositions pharmaceutiques lyophilisées destinées à la thérapie génique par adn nu
JP7843072B2 (ja) * 2022-03-24 2026-04-09 ヘリックスミス カンパニー， リミテッド プラスミドｄｎａを含む液体剤形薬剤学的組成物

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4840892A (en) * 1984-05-15 1989-06-20 Smithkline Beckman Corporation Polynucleotide hybridization probes
US5211960A (en) * 1988-11-29 1993-05-18 Scripps Clinic And Research Foundation Stabilization of leukocytes
US5703055A (en) * 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DE4110962A1 (de) * 1991-04-05 1992-10-08 Bayer Ag Equine herpesviren (ehv), die fremd-dna enthalten, verfahren zu ihrer herstellung und ihre verwendung in impfstoffen

Also Published As

Publication number Publication date
EP1042347A1 (fr) 2000-10-11
JP2001526292A (ja) 2001-12-18
AU1940599A (en) 1999-07-12
EP1042347A4 (fr) 2005-02-16
WO1999032503A1 (fr) 1999-07-01

Similar Documents

Publication Publication Date Title
JP7824985B2 (ja) メッセンジャーｒｎａの皮下送達
JP2022173314A (ja) メッセンジャーｒｎａの皮下送達
RU2201252C2 (ru) Устойчивая, свободная от альбумина лиофилизованная композиция рекомбинантного фактора viii
US20230372440A1 (en) Improved process and formulation of lipid nanoparticles
KR100417593B1 (ko) 트레할로스를포함하는건조혈액인자조성물
CN107567497A (zh) Rna的冻干
JPH0558000B2 (fr)
JP2000500026A (ja) 感染性組換えウイルスの保存方法、水性ウイルス懸濁液、および薬剤としての使用
US7927870B2 (en) DNA vaccine formulations
EP1371373A1 (fr) Interferon supercompose de recombinaison utilise comme inhibiteur de l'antigene de surface et de l'antigene e de l'hepatite b
JP7449243B2 (ja) 安定な融合タンパク質製剤
AU727306B2 (en) DNA vaccine formulations
US6387695B1 (en) DNA pharmaceutical formulations comprising citrate or triethanolamine and combinations thereof
CA2315032A1 (fr) Formulations pharmaceutiques d'adn comportant du citrate ou de la triethanolamine ou des combinaisons de ces composes
EP3319930A1 (fr) Procédés et compositions pour la stabilisation de protéines
US7052875B1 (en) Stable gene preparations
AU2003203737B2 (en) DNA Pharmaceutical Formulations Comprising Citrate or Triethanolamine and Combinations Thereof
RU2809360C1 (ru) РЕКОМБИНАНТНАЯ ПЛАЗМИДА pET32a-IFG144, ОБЕСПЕЧИВАЮЩАЯ СИНТЕЗ ИНТЕРФЕРОНА ГАММА, ШТАММ БАКТЕРИЙ ESCHERICHIA COLI JM109/pET32a-IFG144 - ПРОДУЦЕНТ БЕЛКА ИНТЕРФЕРОН ГАММА, СПОСОБ ПОЛУЧЕНИЯ ИНТЕРФЕРОНА ГАММА И ЛЕКАРСТВЕННОЕ СРЕДСТВО
WO1999045953A1 (fr) Compositions contenant un cofacteur ii de l'heparine et techniques de stabilisation
DK157170C (da) Koncentrat af den anti-hæmofile Faktor VIII samt fremgangsmåde til fremstilling deraf
CN118064427A (zh) 一种质粒dna制剂稳定剂及其应用
EP1094835B1 (fr) Procede de preparation d'une composition pharmaceutique contenant de l'apotransferrine humaine
JPH0348173B2 (fr)
van der Heijden et al. Production and quality control of plasmid DNA vaccines for early oncology clinical trials—a review
JPH0578259A (ja) 改変型 ｔ−ＰＡ 含有組成物

Legal Events

Date Code Title Description
EEER Examination request
FZDE Discontinued